Cargando…
Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
BACKGROUND: Long‐term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D(2) receptor sensitization. We evaluated the effects of brexpiprazole on D(2) receptor sensitivity after subchronic tre...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292306/ https://www.ncbi.nlm.nih.gov/pubmed/31487433 http://dx.doi.org/10.1002/npr2.12076 |
_version_ | 1783546084664016896 |
---|---|
author | Amada, Naoki Akazawa, Hitomi Ohgi, Yuta Maeda, Kenji Sugino, Haruhiko Kurahashi, Nobuyuki Kikuchi, Tetsuro Futamura, Takashi |
author_facet | Amada, Naoki Akazawa, Hitomi Ohgi, Yuta Maeda, Kenji Sugino, Haruhiko Kurahashi, Nobuyuki Kikuchi, Tetsuro Futamura, Takashi |
author_sort | Amada, Naoki |
collection | PubMed |
description | BACKGROUND: Long‐term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D(2) receptor sensitization. We evaluated the effects of brexpiprazole on D(2) receptor sensitivity after subchronic treatment in rats. We also evaluated whether brexpiprazole could suppress enhanced response to D(2) receptors in rats subchronically dosed with another atypical antipsychotic. METHODS: The maximum D(2) receptor density (B (max)) and apomorphine (a D(2) receptor agonist)‐induced stereotypy were measured in rats orally dosed with vehicle, haloperidol (1 mg/kg), or brexpiprazole (4 or 30 mg/kg for B (max), 6 or 30 mg/kg for stereotypy) for 21 days. Then, effects of oral administrations of brexpiprazole (3 mg/kg), aripiprazole (10 mg/kg), and olanzapine (3 mg/kg) against increases in apomorphine‐induced hyperlocomotion and (±)‐2,5‐dimethoxy‐4‐iodoamphetamine hydrochloride (DOI: a 5‐HT(2A) receptor agonist)‐induced head twitches were evaluated in rats subcutaneously treated with risperidone (1.5 mg/kg/d) via minipumps for 21 days. RESULTS: Haloperidol and brexpiprazole (30 mg/kg: approximately tenfold ED(50) of anti‐apomorphine‐induced stereotypy) but not brexpiprazole (4 or 6 mg/kg) significantly increased the B (max) and apomorphine‐induced stereotypy. Brexpiprazole (3 mg/kg) and olanzapine (3 mg/kg) significantly suppressed both increases in apomorphine‐induced hyperlocomotion and also DOI‐induced head twitches in rats subchronically treated with risperidone, but aripiprazole (10 mg/kg) significantly suppressed only apomorphine‐induced hyperlocomotion. CONCLUSION: Brexpiprazole has a low risk of D(2) receptor sensitization after a repeated administration and suppresses the rebound phenomena related to D(2) and 5‐HT(2A) receptors after a repeated administration of risperidone. |
format | Online Article Text |
id | pubmed-7292306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72923062020-12-08 Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats Amada, Naoki Akazawa, Hitomi Ohgi, Yuta Maeda, Kenji Sugino, Haruhiko Kurahashi, Nobuyuki Kikuchi, Tetsuro Futamura, Takashi Neuropsychopharmacol Rep Original Articles BACKGROUND: Long‐term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D(2) receptor sensitization. We evaluated the effects of brexpiprazole on D(2) receptor sensitivity after subchronic treatment in rats. We also evaluated whether brexpiprazole could suppress enhanced response to D(2) receptors in rats subchronically dosed with another atypical antipsychotic. METHODS: The maximum D(2) receptor density (B (max)) and apomorphine (a D(2) receptor agonist)‐induced stereotypy were measured in rats orally dosed with vehicle, haloperidol (1 mg/kg), or brexpiprazole (4 or 30 mg/kg for B (max), 6 or 30 mg/kg for stereotypy) for 21 days. Then, effects of oral administrations of brexpiprazole (3 mg/kg), aripiprazole (10 mg/kg), and olanzapine (3 mg/kg) against increases in apomorphine‐induced hyperlocomotion and (±)‐2,5‐dimethoxy‐4‐iodoamphetamine hydrochloride (DOI: a 5‐HT(2A) receptor agonist)‐induced head twitches were evaluated in rats subcutaneously treated with risperidone (1.5 mg/kg/d) via minipumps for 21 days. RESULTS: Haloperidol and brexpiprazole (30 mg/kg: approximately tenfold ED(50) of anti‐apomorphine‐induced stereotypy) but not brexpiprazole (4 or 6 mg/kg) significantly increased the B (max) and apomorphine‐induced stereotypy. Brexpiprazole (3 mg/kg) and olanzapine (3 mg/kg) significantly suppressed both increases in apomorphine‐induced hyperlocomotion and also DOI‐induced head twitches in rats subchronically treated with risperidone, but aripiprazole (10 mg/kg) significantly suppressed only apomorphine‐induced hyperlocomotion. CONCLUSION: Brexpiprazole has a low risk of D(2) receptor sensitization after a repeated administration and suppresses the rebound phenomena related to D(2) and 5‐HT(2A) receptors after a repeated administration of risperidone. John Wiley and Sons Inc. 2019-09-05 /pmc/articles/PMC7292306/ /pubmed/31487433 http://dx.doi.org/10.1002/npr2.12076 Text en © 2019 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of NeuropsychoPharmacology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Amada, Naoki Akazawa, Hitomi Ohgi, Yuta Maeda, Kenji Sugino, Haruhiko Kurahashi, Nobuyuki Kikuchi, Tetsuro Futamura, Takashi Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats |
title | Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats |
title_full | Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats |
title_fullStr | Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats |
title_full_unstemmed | Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats |
title_short | Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats |
title_sort | brexpiprazole has a low risk of dopamine d(2) receptor sensitization and inhibits rebound phenomena related to d(2) and serotonin 5‐ht(2a) receptors in rats |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292306/ https://www.ncbi.nlm.nih.gov/pubmed/31487433 http://dx.doi.org/10.1002/npr2.12076 |
work_keys_str_mv | AT amadanaoki brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats AT akazawahitomi brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats AT ohgiyuta brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats AT maedakenji brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats AT suginoharuhiko brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats AT kurahashinobuyuki brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats AT kikuchitetsuro brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats AT futamuratakashi brexpiprazolehasalowriskofdopamined2receptorsensitizationandinhibitsreboundphenomenarelatedtod2andserotonin5ht2areceptorsinrats |